Targeted therapy with a localized abluminal groove low-dose sirolimus-eluting bioabsorbable polymer coronary stent in chronic total occlusions: The TARGET CTO non-inferiority randomized trial
Primary result · In-stent late lumen loss (LLL)Result — go to the resultDifference (BP-SES minus DP-EES) 0.01 mm 95% CI −0.13 to 0.12Authors' conclusion
Compared to DP-EES, PCI of CTOs with BP-SES showed similar results in terms of late loss and binary restenosis at the 12-month follow-up.
Study context
- Population
- Patients undergoing percutaneous coronary intervention (PCI) for chronic total occlusions (CTOs)subjects randomized · BP-SES 103 · DP-EES 103
- Participants
- 206 patients
- Comparison
- BP-SES vs DP-EES in PCI for CTOs
- BP-SESn = 103
- DP-EESn = 103
- Primary endpoint
- In-stent late lumen loss (LLL)
- Follow-up
- 12 months
Methodological detailsrandomized 1:1 following successful CTO re-canalization
- Randomized 1:1 following successful CTO re-canalization
Primary result
As reported in the abstract
Difference (BP-SES minus DP-EES)
0.01 mm
95% CI −0.13 to 0.12
P < 0.001,1-sided for non-inferiority
By group
BP-SES vs DP-EES
difference (BP-SES minus DP-EES) 0.01 mm (95% CI −0.13 to 0.12); P for non-inferiority < 0.001,1-sided
Further findings
In-stent binary restenosis · 12 months
P = 0.86
In-segment binary restenosis · 12 months
P = 0.89
Target lesion failure · 12 months · trend favoring BP-SES, not statistically significant
P = 0.054
Target lesion revascularization · 12 months · not statistically significant
P = 0.089
Secondary angiographic or clinical endpoints
- No significant differences
Safety
Definite or probable stent thrombosis
- None reported in either group
Original publication
Targeted therapy with a localized abluminal groove low-dose sirolimus-eluting bioabsorbable polymer coronary stent in chronic total occlusions: The TARGET CTO non-inferiority randomized trial. Am Heart J. Published 3 February 2025. doi:10.
Summarised from the published abstract; every number is checked against it